香港联交所最新数据显示，9月15日，FIDELITY FUNDS减持昭衍新药（603127）(06127)171.13万股， 每股作价20.4757港元，总金额约为3504.01万港元。减持后最新持股数目1114.34万股，持股比例为 9.36%。 ...

Group 1: New Stock Issuances - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 11 trading days remaining until the last trading day during the delisting arrangement period[1] - *ST Dongtong (300379) has reported severe abnormal fluctuations in stock price[1] Group 2: Market Alerts - Jiushi Media (601929) has experienced significant abnormal fluctuations in stock price[1] - Xian Dao Intelligent (300450) has reported severe abnormal fluctuations in stock price[1] - Hangke Technology (688006) has issued a notice regarding stock performance[1] Group 3: Trading Notifications - Shanghai Construction (600170) has issued a trading notification on September 18, 2025[1] - Junsheng Electronics (600699) has issued a trading notification on September 18, 2025[1] - ST Changyuan (600525) has issued a trading notification on September 18, 2025[1]

New Stock Issuance - Cash option declaration period for *ST Tianmao (000627) is from September 15 to September 19, 2025[1] - *ST Zitian (300280) has 12 trading days remaining until the last trading day during the delisting arrangement period[1] Trading Alerts - *ST Jishi Media (601929) reported severe abnormal fluctuations in stock price[1] - *ST Yushun (002289) and *ST Weier (002058) are under scrutiny due to abnormal trading activities[1] Company Announcements - *ST Gao Hong (000851) and *ST Dongtong (300379) have recent announcements regarding their financial status[1] - Shanghai Construction (600170) and Zhongke Shuguang (603019) have disclosed important updates on their operations[1] Market Trends - The report indicates a trend of increased scrutiny on companies with abnormal trading patterns, reflecting a tightening regulatory environment[2] - The number of companies under cash option declarations and delisting arrangements suggests a potential increase in market volatility[1]

Core Points - On September 17, Zhaoyan New Drug fell by 5.02%, trading at 40.08 CNY per share, with a transaction volume of 1.58 billion CNY and a turnover rate of 6.16%, resulting in a total market capitalization of 30.039 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs and preclinical research services, as well as the sale of laboratory animals and related products [1] Shareholder Analysis - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) increased its holdings by 2.2669 million shares in the second quarter, holding a total of 14.6531 million shares, which accounts for 1.96% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 31.0646 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a latest scale of 26.147 billion CNY, and has achieved a year-to-date return of 21.64% [2]

New Stock Issuance - Jin Hua New Material (920015) issued at a price of 18.15[1] - Jianfa Zhixin (301584) issued at a price of 7.05[1] Market Alerts - Cash option declaration period for *ST Tianmao (000627) from September 15 to September 19, 2025[1] - 13 trading days remaining for the delisting period of Zitian Tui (300280)[1] - Severe abnormal fluctuation reported for Jishi Media (601929)[1] Other Announcements - Multiple companies including Shanghai Construction (600170) and Zhongke Shuguang (603019) have recent announcements linked[1] - Various stocks are under scrutiny for abnormal trading activities, including *ST Yu Shun (002289) and ST Huaneng (000851)[3]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Core Viewpoint - The company, Zhaoyan New Drug (603127), experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days in September 2025, prompting an investigation into the reasons behind this abnormal trading behavior [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external business environment that would affect the stock price [1]. - There is no undisclosed major information that could impact the stock price [1]. Group 2: Major Events - The company conducted a self-examination and consulted with its controlling shareholders and actual controllers, confirming that there are no major events affecting stock price fluctuations, such as major asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially impact the stock price [3]. Group 4: Sensitive Information - The company verified that there were no transactions involving the company's stock by its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].

Core Viewpoint - The company, Zhaoyan New Drug (06127), announced that its A-share stock experienced a cumulative price fluctuation exceeding 20% over three consecutive trading days, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external operating environment that would affect the stock price [1]. Group 2: Major Events - A self-examination by the company and inquiries with its controlling shareholders revealed no major events that could impact the stock price, including significant asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially affect the stock price [3]. Group 4: Other Price-Sensitive Information - The company verified that there were no transactions involving its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年9月15日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-040 北京昭衍新药研究中心股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （三）媒体报道、市场传闻、热点概念情况 一、股票交易异常波动的具体情况 公司股票于 2025 年 9 月 11 日、9 月 12 日和 9 月 15 日连续 3 个交易日内日 收盘价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规 定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，现将有关情况说 明如下： （一）生产经营情况 经自查，公司目前生产经营活动正常，内、外部经营环境未发生重大变化， 不存在影响公司股票交易价格异常波动的应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，不存 在影响公司股票交易价格异常波动的重大事项，不存在涉及公司应披露而未披露 的重大信息，包括但不限于重大资产重组、 ...